

Supplementary Material




Figure S1. Flow diagram of patient recruitment

*Patients were excluded from the analysis due to impossibility of clinical data collection in some centers during turbulent periods of the pandemic or no confirmation of SARS-CoV2 infection.

Table S1. Troponin assays.

Troponin assay	99 th percentile URL (ng/L)*		
	Overall	Male	Female
Vitros Fusion 5.1 Troponin I hs	11	13	9
BioMérieux VIDAS 3 Troponin I hs	19	25	11
ADVIA Centaur Troponin I hs	47	57	37
XT 76000 Troponin I hs	11	13	9
Vitros 5600 Troponin hs	11	13	9
Roche cTnT-hs STAT on cobas e 601, 602, E170; commercial	14	16	9
Abbott / ARCHITECT I systems / hs Troponin-I	26.2	34.2	15.6

URL, upper reference limit. *According to manufacturer.

Table S2. Baseline characteristics of patients according to serum troponin levels.

Characteristics	All patients (n=3246)	Troponin levels (URL)					χ^2 test P-value
		$\leq 1x$ (n=1123; 34.6%)	> 1 to $3x$ (n=127; 3.9%)	> 3 to $10x$ (n=87; 2.7%)	$> 10x$ (n=139; 4.3%)	Not measured (n=1770; 54.5%)	
Sex, No (%)							
Male	1935 (59.6)	667 (34.5)	85 (4.4)	59 (3.0)	84 (4.3)	1040 (53.7)	0.210
Female	1311 (40.4)	456 (34.8)	42 (3.2)	28 (2.1)	55 (4.2)	730 (55.7)	
Age, No (%)							
< 40 years	603 (18.6)	235 (39.0)	5 (0.8)	6 (1.0)	8 (1.3)	349 (57.9)	< 0.001
40 to 59 years	1357 (41.8)	524 (38.6)	30 (2.2)	20 (1.5)	35 (2.6)	748 (55.1)	
60 to 69 years	541 (16.7)	174 (32.2)	29 (5.4)	21 (3.9)	36 (6.7)	281 (51.9)	
≥ 70 years	745 (23.0)	190 (25.5)	63 (8.5)	40 (5.4)	60 (8.1)	392 (52.6)	
O₂ Sat, No (%)							
$\geq 94\%$	2327 (71.7)	832 (35.8)	84 (3.6)	45 (1.9)	94 (4.0)	1272 (54.7)	< 0.001
$\leq 93\%$	919 (28.3)	291 (31.7)	43 (4.7)	42 (4.6)	45 (4.9)	498 (54.2)	
Diabetes, No (%)							
No	2434 (75)	869 (35.7)	84 (3.5)	55 (2.3)	95 (3.9)	1331 (54.7)	0.001
Yes	812 (25)	254 (31.3)	43 (5.3)	32 (3.9)	44 (5.4)	439 (54.1)	
Hipertension, No (%)							
No	1403 (43.2)	526 (37.5)	27 (1.9)	20 (1.4)	41 (2.9)	789 (56.2)	< 0.001
Yes	1843 (56.8)	597 (32.4)	100 (5.4)	67 (3.6)	98 (5.3)	981 (53.2)	
Heart Failure, No (%)							
No	3145 (96.9)	1103 (35.1)	113 (3.6)	81 (2.6)	131 (4.2)	1717 (54.6)	< 0.001
Yes	101 (3.1)	20 (19.8)	14 (13.9)	6 (5.9)	8 (7.9)	53 (52.5)	
Coronary disease, No (%)							
No	3029 (93.3)	1060 (35.0)	103 (3.4)	76 (2.5)	124 (4.1)	1666 (55.0)	< 0.001
Yes	217 (6.7)	63 (29.0)	24 (11.1)	11 (5.1)	15 (6.9)	104 (47.9)	
Chronic heart disease, No (%)							
No	3079 (94.9)	1075 (34.9)	111 (3.6)	76 (2.5)	122 (4.0)	1695 (55.1)	< 0.001
Yes	167 (5.1)	48 (28.7)	16 (9.6)	11 (6.6)	17 (10.2)	75 (44.9)	
Chronic kidney disease, No (%)							
No	3094 (95.3)	1094 (35.4)	118 (3.8)	77 (2.5)	129 (4.2)	1676 (54.2)	< 0.001
Yes	152 (4.7)	29 (19.1)	9 (5.9)	10 (6.6)	10 (6.6)	94 (61.8)	

URL, upper reference limit, O₂ sat, oxygen saturation.

Table S3. In-hospital mortality according to troponin level in the first week.

Troponin	All patients n (%)	In-hospital mortality			χ^2 test p-Value
		No n (%)	Yes n (%)	CI95%	
≤ 1 x URL (no injury)	1123 (100)	1061 (94.5)	62 (5.5)	4.3 - 7.0	< 0.001
>1x URL (injury)	353 (100)	273 (77.3)	80 (22.7)	18.5– 27.3	
> 1 to 3x URL	127 (100)	110 (86.6)	17 (13.4)	8.3 - 20.2	
> 3 to 10x URL	87 (100)	67 (77.0)	20 (23.0)	15.1 - 32.7	< 0.001
> 10x URL	139 (100)	96 (69.1)	43 (30.9)	23.7 - 39.0	
Measured	1476 (100)	1334 (90.4)	142 (9.6)	8.2–11.2	
Not measured	1770 (100)	1559 (88.1)	211 (11.9)	10.5 - 13.5	0.04
All patients	3246 (100)	2893 (89.1)	353 (10.9)	9.8 - 12.0	

CI, confidence interval; URL, upper reference limit.

Table S4. In-hospital mortality by complications (*n* = 3246).

Complications	In-hospital mortality	RR	c ² test P-value
Thromboembolic phenomena			
No	10.3%	1	< 0,001
Yes	25.8%	2.5	
Stroke or TIA			
No	10.7%	1	0.017
Yes	18.5%	1.7	
Myopericarditis			
No	10.7%	1	0.003
Yes	24.4%	2.3	
Myocardial ischemia*			
No	10.4%	1	< 0,001
Yes	33.3%	3.2	
Acute renal failure			
No	4.7%	1	< 0,001
Yes	57.6%	12.3	
Sepsis or septic shock			
No	5.8%	1	< 0,001
Yes	54.0%	9.3	
Invasive ventilation			
No	1.4%	1	< 0,001
Yes	51.0%	36.4	

*Acute myocardial infarction, myocardial ischemia, or coronary intervention.

RR, relative risk; TIA, transient ischemic attack.

Table S5. Complications according to troponin measurement ($n = 3246$).

Complications	Total (n=3246) n (%)	Incidence Troponin		c ² test p-value
		Measured n (%)	Not measured n (%)	
Thromboembolic phenomena	120 (3.7)	43 (2.9)	77 (4.4)	0.31
Stroke or TIA	92 (2.8)	45 (3.0)	47 (2.7)	0.501
Myopericarditis	45 (1.4)	30 (2.0)	15 (0.8)	0.004
Heart failure	82 (2.5)	39 (2.6)	44 (2.5)	0.873
Myocardial ischemia	72 (2.2)	48 (3.3)	24 (1.4)	< 0.001
Sepsis or septic shock	339 (10.4)	175 (11.8)	165 (9.3)	0.022
Acute renal failure	380 (11.7)	160 (10.8)	220 (12.4)	0.161
Invasive ventilatory support	621 (19.1)	250 (16.9)	371 (21.0)	0.004

TIA, transient ischemic attack.